Cadila Pharmaceuticals Ltd.
Records under this name other than the patents Cadila Pharmaceuticals Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 9 patents it holds.
Back to Cadila Pharmaceuticals Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,795,659 | Pharmaceutical composition of killed cells with substantially retained immunogenicity Lapsed on the fee record Ended Oct 24, 2025 · USPTO record | Lapsed on the fee record | Ended Oct 24, 2025 | USPTO record |
| US 8,563,517 | Dipeptidyl peptidase IV (DP-IV) compounds Lapsed on the fee record Ended Oct 22, 2025 · USPTO record | Lapsed on the fee record | Ended Oct 22, 2025 | USPTO record |
| US 9,708,258 | Indole 3-carbinol derivatives Lapsed on the fee record Ended Jul 18, 2025 · USPTO record | Lapsed on the fee record | Ended Jul 18, 2025 | USPTO record |
| US 8,048,434 | Vaccine adjuvants Lapsed on the fee record Ended Nov 1, 2023 · USPTO record | Lapsed on the fee record | Ended Nov 1, 2023 | USPTO record |
| US 7,972,609 | Method of treating cancer Lapsed on the fee record Ended Jul 5, 2023 · USPTO record | Lapsed on the fee record | Ended Jul 5, 2023 | USPTO record |
| US 9,029,567 | Hypoglycemic compounds Lapsed on the fee record Ended May 12, 2023 · USPTO record | Lapsed on the fee record | Ended May 12, 2023 | USPTO record |
| US 8,647,643 | Farnesoid-X-receptor antagonist as a vaccine adjuvant Lapsed on the fee record Ended Feb 11, 2018 · USPTO record | Lapsed on the fee record | Ended Feb 11, 2018 | USPTO record |
| US 8,277,778 | Vaccine adjuvants Lapsed on the fee record Ended Oct 2, 2016 · USPTO record | Lapsed on the fee record | Ended Oct 2, 2016 | USPTO record |
| US 8,153,102 | Process for manufacturing pharmaceutical composition comprises of Mycobacterium w in the treatment of asthma (obstructive lung disease) Lapsed on the fee record Ended Apr 10, 2016 · USPTO record | Lapsed on the fee record | Ended Apr 10, 2016 | USPTO record |
| US 8,110,204 | Method of treating human-immunodeficiency virus (HIV) disease infection Lapsed on the fee record Ended Feb 7, 2016 · USPTO record | Lapsed on the fee record | Ended Feb 7, 2016 | USPTO record |